deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02339168

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in Castration Resistant Prostate Cancer

Sponsor: Astellas Pharma Inc

Conditions Prostate Cancer
Interventions Enzalutamide Metformin Hydrochloride
Updated 17 times since 2017 Last updated: Apr 29, 2025 Started: Jun 22, 2016 Primary completion: Oct 15, 2024 Completion: Feb 24, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02339168, this PHASE1 trial focuses on Prostate Cancer and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 17 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Feb 2019 · 7 months · monthly snapshot~Feb 2019 – ~Oct 2019 · 8 months · monthly snapshot~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~Oct 2020 · 8 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Nov 2022 · 9 months · monthly snapshot~Nov 2022 – ~Sep 2023 · 10 months · monthly snapshot~Sep 2023 – ~Jun 2024 · 9 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

17 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 12 earlier versions

  1. Nov 2022 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Feb 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  8. Oct 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  9. Feb 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1

  10. Jul 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  11. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  12. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Astellas Pharma Inc
  • Medivation, Inc.
  • National Cancer Institute (NCI)
  • University of California, Davis
Data source: University of California, Davis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations